Medicinal agent for treating amyotrophic lateral sclerosis or preventing progression of phase of amyotrophic lateral sclerosis

Abstract

The purpose of the present invention is to provide a novel medicinal agent and a novel method both of which can be used for treating ALS (amyotrophic lateral sclerosis), preventing the progression of the phase of ALS, treating a symptom associated with ALS, or preventing the progression of the phase of the symptom, and both of which can be particularly applied to patients who can be treated by the medicinal agent or the method highly effectively among ALS patients who are needed to be treated. According to the present invention, a medicinal agent which can be used for treating amyotrophic lateral sclerosis, preventing the progression of the phase of amyotrophic lateral sclerosis, treating a symptom associated with amyotrophic lateral sclerosis, or preventing the progression of the phase of the symptom is provided. The medicinal agent comprises 3-methyl-1-phenyl-2-pyrazolin-5-one or a physiologically acceptable salt thereof as an active ingredient, is administered in such a manner that a 14-day dosing period and a 14-day washout period are repeated alternately or in such a manner that a 14-days initial dosing period and a subsequent 14-day initial washout period are set and subsequently a dosing period in which the dosing is carried out for any 10 days of 14 days and a 14-day washout period are repeated alternately, and is administered to a patient who meets specific criteria.

Description

technical field [0001] The present invention relates to an agent for treating or inhibiting the progression of amyotrophic lateral sclerosis (hereinafter, sometimes referred to as ALS), or for treating or inhibiting the progression of symptoms caused by ALS. Background technique [0002] ALS, one of the motor neuron diseases, progresses from initial symptoms such as hand weakness, movement disorder of the fingers, and contracture of fiber bundles of the upper limbs to respiratory failure through muscle atrophy, muscle weakness, bulbar palsy, and contracture of muscle fiber bundles. Refractory disease. ALS is divided into upper extremity type, bulbar type, lower extremity type, and mixed type according to the location of symptoms, and any type invades the muscles of the whole body as symptoms progress. The etiology of ALS has not yet been fully elucidated, but as the main etiology, (1) autoimmune theory (appearance of autoantibodies against Ca channels), (2) excitatory amino...

AI Technical Summary

Problems solved by technology

In Patent Document 1, although it is suggested or taught that 3-methyl-1-phenyl-2-pyrazolin-5-one is useful for ALS treatment, it does not specifically disclose the administration method and administration amount to patients and the number of administrations, etc.

Images